IPCA Laboratories · NSE: IPCALAB · BSE: 524494

Q1 FY23 results · Apr–Jun 2022

IPCA Laboratories reported revenue from operations of ₹1,585.74 crore (up 1.3% from Q1 FY22) and net profit of ₹145.24 crore (down 52.6% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY23	Q1 FY22	YoY	Q4 FY22	QoQ
Revenue from operations	1,585.74	1,565.79	+1.3%	1,289.10	+23.0%
Other income	22.11	21.02	+5.2%	14.54	+52.1%
Total income	1,607.85	1,586.81	+1.3%	1,303.64	+23.3%
Profit before share of associates & JVs and tax	222.69	379.87	−41.4%	169.55	+31.3%
Share of profit/(loss) of associates & JVs	(3.19)	(2.43)		(8.81)
Net profit for the period	145.24	306.67	−52.6%	131.98	+10.0%
Attributable to shareholders of the company	143.06	306.66	−53.3%	130.23	+9.9%
EPS, basic (₹)	5.64	24.18	not comparable	5.13	+9.9%
Net margin (%)	9.2	19.6		10.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY23	Q1 FY22	YoY	Q4 FY22	QoQ
Revenue from operations	1,469.28	1,478.60	−0.6%	1,168.45	+25.7%
Other income	18.81	13.61	+38.2%	14.21	+32.4%
Total income	1,488.09	1,492.21	−0.3%	1,182.66	+25.8%
Profit before tax	216.06	356.37	−39.4%	137.63	+57.0%
Net profit for the period	143.82	284.72	−49.5%	110.41	+30.3%
EPS, basic (₹)	5.67	22.45	not comparable	4.35	+30.3%
Net margin (%)	9.8	19.3		9.4

Consolidated

Filed with BSE: 11 Aug 2022, 12:53 IST
Board meeting: 10 Aug 2022
Period: 01 Apr 2022 to 30 Jun 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 11 Aug 2022, 12:53 IST
Board meeting: 10 Aug 2022
Period: 01 Apr 2022 to 30 Jun 2022
Review status: Unaudited
Source: XBRL filing on BSE